Horizon 2020: Discovery and validation of novel endpoints in dry age-related macular degeneration and diabetic retinopathy

Treatment for common retinal conditions such as the dry form of AMD (dry AMD) or diabetic retinopathy (DR) is limited. One major development hurdle is the lack of suitable, patient-relevant study endpoints with clinical relevance for both early exploratory and pivotal trials.

The European Commission invites proposals to evaluate novel endpoint candidates for dry AMD and DR. The evaluation should cover the technical, medical and health economic appropriateness of a method and bridge preclinical and clinical studies. The project should provide generation of adequate data resulting from robust retrospective and/or prospective studies in patients that could serve as basis for initial discussion with regulatory agencies and/or HTA-bodies for acceptance of the resulting outcomes as endpoints for future clinical programs.

The deadline for applicatinos is 12 November 2014. Please visit the Horizon 2020 website for further details.